# AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis

> **NCT01228396** · PHASE2 · UNKNOWN · sponsor: **Daval International Limited** · enrollment: 20 (actual)

## Conditions studied

- Secondary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Hyperimmune caprine serum against HIV lysate

## Key facts

- **NCT ID:** NCT01228396
- **Lead sponsor:** Daval International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-05
- **Primary completion:** 2011-05
- **Final completion:** 2012-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2011-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01228396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01228396, "AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01228396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*